Sanofi to use DiCE Molecules’ platform to boost drug discovery
March 16, 2016Research and Development DiCE Molecules, Sanofi
Sanofi has announced a research partnership with newly-launched DiCE Molecules in which the French pharma giant will use DiCE’s small …
Teva says closing buy of Allergan’s generics biz may take longer
March 16, 2016Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva
Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …
Lilly changes Alzheimer’s trial endpoint – shares fall
March 16, 2016Research and Development Alzheimer's disease, Eli Lilly, solanezumab
Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …
UPDATE: InVivo Therapeutics prices public offering at $7.50 per share to raise $28 million
March 15, 2016Business Services, Manufacturing and Production, Sales and Marketing InVivo, Share price, Stake sale
InVivo Therapeutics (Nasdaq: NVIV) on Tuesday said it plans to raise about $28 million via a public offering of over …
Valeant cuts 2016 sales, earnings outlook; shares plunge over 47%
March 15, 2016Business Services, Manufacturing and Production, Sales and Marketing Valeant Pharma, fourth quarter, full year, results
Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …
Cellnovo, Roche sign deal to integrate diabetes platforms
March 15, 2016Manufacturing and Production, Sales and Marketing Cellnovo, Roche, diabetes
Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug major Roche (Euronext: ROG) to …
InVivo Therapeutics to sell stake in company; shares drop
March 15, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing InVivo Therapeutics, Stake sale, stocks
InVivo Therapeutics (Nasdaq: NVIV) said it plans to sell an additional stake in the company to raise funds for its ongoing …
Basilea nominates Domenico Scala as new chairman
March 15, 2016Business Services, Manufacturing and Production Basilea, Chariman, Executive appointment
Switzerland-based Basilea Pharmaceutica on Tuesday nominated Domenico Scala as the new chairman of the board. The current Chairman, Martin Nicklasson …
PTC Therapeutics to file new Phase III data for genetic muscle disorder drug in Canada
March 15, 2016Manufacturing and Production, Research and Development Canada, PTC Therapeutics, Translarna, nonsense mutation Duchenne muscular dystrophy, phase III
PTC Therapeutics (Nasdaq: PTCT) said it does not expect the Canadian regulators to review its trial drug to treat a …
Adocia and Lilly report positive early results for ultra-rapid insulin
March 15, 2016Manufacturing and Production, Research and Development Adocia, BioChaperone Lispro, Eli Lilly, insulinm
Eli Lilly and development partner Adocia have announced today positive topline results from a Phase 1b clinical trial of ultra-rapid …
UPDATE: Pfizer gets interim stay on cough syrup ban
March 15, 2016Manufacturing and Production, Research and Development Abbott Laboratories, Corex, Pfizer, Pfizer India
Shares in Pfizer India continued to tumble for a second day even as an Indian court granted the company a …
Genentech cancer immunotherapy gets Priority FDA Review in bladder cancer
March 15, 2016Manufacturing and Production, Research and Development FDA, Genentech, Roche, atezolizumab, bladder cancer, priority review
The US FDA has granted Roche subsidiary Genentech a Priority Review for atezolizumab in treating advanced bladder cancer, whose disease …
GW Pharma shares more than double after positive Phase III trials for epilepsy drug
March 15, 2016Manufacturing and Production, Research and Development Epidiolex, GW Pharma, US FDA, epilepsy in children, phase III
Shares in UK-based GW Pharmaceuticals (Nasdaq: GWPH) more than doubled on the Nasdaq Monday after the company announced positive results …
COMMENT: What does Amarin’s off-patent victory over the FDA mean for the industry?
March 14, 2016Medical Communications, Sales and Marketing Amarin, FDA, off label, off-label, vascepa
Last week, Pharmafile.com reported that small biopharma Amarin had settled litigation with US drugs regulator the FDA that will allow …
Cambridge Epigenetix says raised $21 million, appoints Geoff Smith CEO
March 14, 2016Business Services, Sales and Marketing CEGX, CEO, Cambridge Epigenetix, fundraising, genome sequencing
Cambridge Epigenetix (CEGX) on Monday said it has raised about $21 million via Series B financing and named Geoff Smith …
Ariad names Manmeet Soni CFO
March 14, 2016Business Services, Sales and Marketing Ariad, CEO, appointment, boardroom, cfo
Ariad Pharmaceuticals Inc (Nasdaq: ARIA) named Manmeet Soni chief financial officer, effective March 21, 2016, succeeding Edward Fitzgerald. Mr Soni will …
Janssen’s Zytiga boosts survival in early-stage prostate cancer
March 14, 2016Research and Development, Sales and Marketing Janssen, Zytiga, abiraterone, prednisone, prostate cancer
Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall …
FDA approves Pfizer sNDA for Xalkori
March 14, 2016Research and Development, Sales and Marketing Cancer, EMA, NSCLC, Pfizer, Xalkori (crizotinib)
The US FDA has approved Pfizer’s supplemental new drug application (sNDA) for its kinase inhibitor Xalkori in treating patients with …
EMA starts review of Gilead Sciences’ Zydelig following safety concerns
March 14, 2016Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig
Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …
GSK terminates Five Prime Therapeutics mesothelioma collaboration
March 14, 2016Research and Development, Sales and Marketing Five Prime Therapeutics, GSK, mesothelioma
GSK is to back out of a licensing deal with California-based Five Prime Therapeutics to develop a mesothelioma drug. Announcing …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
